Background: The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. Patients and Methods: The data from 1532 consecutive patients who presented to the emergency unit of our institute from 2004 to 2012 because of gross hematuria as a single symptom were evaluated. Patients (n= 227) with a further diagnosis of BCa were included in our study. For the purpose of the present study, patients were divided into 2 groups: patients receiving antiplatelet or anticoagulant therapy (AAT) (group 1) and patients not receiving AAT (group 2) at the moment of the macroscopic hematuria episode. The effect of AAT on the pathologic stage and grade of BCa was statistically assessed using univariate and multivariate logistic regression analysis. Results: A total of 59 (26%) and 168 (74%) patients were included in groups 1 and 2, respectively. On multivariate logistic regression analysis, ATT conferred a protective effect against both pathologic stage≥ T2 (odds ratio [OR], 0.37; 95% confidential interval [CI], 0.12-0.66; P= .01) and higher grade (OR, 0.56; 95% CI, 0.26-0.85; P = 02) at tumor presentation. Conclusion: According to the results of the present retrospective investigation, patients who received AAT seem to experience gross hematuria significantly earlier than do untreated patients, resulting in the chance of an earlier diagnosis and treatment of bladder cancer.

Moschini, M., Karnes, R., Suardi, N., Bianchi, M., Pellucchi, F., Rocchini, L., et al. (2016). Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. CLINICAL GENITOURINARY CANCER, 14(3), 245-250 [10.1016/j.clgc.2015.08.003].

Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer

SERRETTA, Vincenzo;
2016-01-01

Abstract

Background: The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. Patients and Methods: The data from 1532 consecutive patients who presented to the emergency unit of our institute from 2004 to 2012 because of gross hematuria as a single symptom were evaluated. Patients (n= 227) with a further diagnosis of BCa were included in our study. For the purpose of the present study, patients were divided into 2 groups: patients receiving antiplatelet or anticoagulant therapy (AAT) (group 1) and patients not receiving AAT (group 2) at the moment of the macroscopic hematuria episode. The effect of AAT on the pathologic stage and grade of BCa was statistically assessed using univariate and multivariate logistic regression analysis. Results: A total of 59 (26%) and 168 (74%) patients were included in groups 1 and 2, respectively. On multivariate logistic regression analysis, ATT conferred a protective effect against both pathologic stage≥ T2 (odds ratio [OR], 0.37; 95% confidential interval [CI], 0.12-0.66; P= .01) and higher grade (OR, 0.56; 95% CI, 0.26-0.85; P = 02) at tumor presentation. Conclusion: According to the results of the present retrospective investigation, patients who received AAT seem to experience gross hematuria significantly earlier than do untreated patients, resulting in the chance of an earlier diagnosis and treatment of bladder cancer.
2016
Settore MED/24 - Urologia
Moschini, M., Karnes, R., Suardi, N., Bianchi, M., Pellucchi, F., Rocchini, L., et al. (2016). Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. CLINICAL GENITOURINARY CANCER, 14(3), 245-250 [10.1016/j.clgc.2015.08.003].
File in questo prodotto:
File Dimensione Formato  
ClinGenUrinCancer_2016.pdf

Solo gestori archvio

Descrizione: lavoro per esteso on line
Dimensione 281.7 kB
Formato Adobe PDF
281.7 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/203144
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact